To the Editor: In a recent issue of Blood, Pane et al[1][1] reported on five cases of mild Phi+ myeloproliferative disorders characterized by a c3/a2 junction in the BCR/ABL hybrid gene transcript and suggested to use the term “neutrophilic chronic myeloid leukemia (N-CML)” to distinguish a “
No takes yet. Share an insight, caveat, or question.
Macro et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: